Feb 17 (Reuters) - STAAR Surgical Co STAA.O:
FDA EXPANDS U.S. AGE INDICATION FOR EVO ICL AS LONG-TERM SAFETY DATA REINFORCES MARKET SHIFT AWAY FROM LASER VISION CORRECTION
STAAR SURGICAL CO - FDA EXTENDS EVO ICL USE TO PATIENTS 21-60 YEARS OLD
Source text: ID:nBw1pM85Va
Further company coverage: STAA.O
((Reuters.Briefs@thomsonreuters.com;))